Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Ultragenyx Pharmaceutical Inc. (RARE) had Weighted-Average Shares Outstanding (Diluted) of 98.60M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$673.00M |
|
$-575.00M |
|
$109.00M |
|
$564.00M |
|
$1.21B |
|
$-535.00M |
|
$-36.00M |
|
$-571.00M |
|
$-571.00M |
|
$-575.00M |
|
$-575.00M |
|
$-575.00M |
|
$-575.00M |
|
$-535.00M |
|
$-504.00M |
|
98.60M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
98.60M |
$-5.83 |
|
$-5.83 |
|
| Balance Sheet Financials | |
$951.00M |
|
$244.00M |
|
$581.00M |
|
$1.53B |
|
$384.00M |
|
-- |
|
$1.23B |
|
$1.61B |
|
$-80.00M |
|
$-300.00M |
|
$-80.00M |
|
96.60M |
|
| Cash Flow Statement Financials | |
$-466.00M |
|
$236.00M |
|
$478.00M |
|
$184.00M |
|
$436.00M |
|
$252.00M |
|
$153.00M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.48 |
|
-- |
|
-- |
|
-- |
|
-- |
|
83.80% |
|
-79.49% |
|
-79.49% |
|
-74.89% |
|
-84.84% |
|
-85.44% |
|
$-472.00M |
|
-- |
|
-- |
|
-- |
|
0.44 |
|
2.10 |
|
4.26 |
|
85.69 |
|
718.75% |
|
191.67% |
|
-37.53% |
|
718.75% |
|
$-0.83 |
|
$-4.79 |
|
$-4.73 |
|